Aptose Biosciences (NASDAQ:APTO) Earns Hold Rating from Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report issued on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of Aptose Biosciences in a research note on Wednesday, February 12th.

Aptose Biosciences Price Performance

Shares of NASDAQ APTO opened at $3.64 on Tuesday. Aptose Biosciences has a 1-year low of $3.11 and a 1-year high of $58.20. The business’s 50 day moving average is $6.09 and its two-hundred day moving average is $8.98. The stock has a market capitalization of $234.05 million, a P/E ratio of -1.23 and a beta of 0.88.

Institutional Trading of Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp lifted its position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 401,750 shares of the biotechnology company’s stock after buying an additional 167,282 shares during the quarter. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent quarter. 26.62% of the stock is currently owned by institutional investors.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.